José Baselga
1,371 works · 116,109 citations · h-index 143
Top works
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
- The landscape of somatic copy-number alteration across human cancers
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
- Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer